In addition to promising results observed with baricitinib treatment in patients with RA, baricitinib may inhibit multiple JAK/STAT-dependent cytokine pathways associated with JIA-uveitis and ANA-positive uveitis pathogenesis and provide a novel therapeutic approach to disease management. Here, SOAT1 is linked to juvenile idiopathic arthritis.